Sermorelin

Ben Greenfield uses the example of combining blood pressure-lowering drugs, nitric oxide precursors, and tadalafil to illustrate the danger of mechanistic redundancy, then extends this principle directly to peptides like ipamorelin and sermorelin. He warns that stacking multiple compounds targeting the same pathway — even if each is individually safe — can produce exponentially amplified side effects such as orthostatic hypotension. This is presented as a critical knowledge gap among biohackers who build peptide stacks without understanding overlapping mechanisms.

Ben Greenfield warns that ipamorelin, sermorelin, and MK-677 all target the same growth hormone receptors and stacking them creates exponentially compounded side effects without proportional benefit. He uses this as an example of how biohackers create dangerous redundancy by combining compounds with overlapping mechanisms of action. No specific dosages are mentioned, but the warning applies to any combination of these GH-axis compounds.

Ben Greenfield explicitly flags the practice of combining multiple growth hormone secretagogues (ipamorelin, sermorelin, MK-677) as a significant safety concern due to shared receptor targets. The redundancy not only wastes cost but creates compounded side effects that users may not anticipate. This is presented as a broader principle: understanding mechanisms of action is essential before stacking any peptides or compounds.

Ben Greenfield warns that ipamorelin, sermorelin, and MK-677 all target the same growth hormone-releasing pathways, meaning stacking them creates redundancy without additive benefit while exponentially compounding side effects. He uses this as an example of how biohackers who lack mechanistic understanding create dangerous redundancy in their supplement and peptide stacks. No specific dosages are mentioned, but the warning applies broadly to any combination of GH secretagogues.

The speaker briefly references 'a serog' (sermorelin) as an alternative to direct GH administration for achieving fat loss benefits during a calorie deficit. This suggests the speaker views sermorelin as functionally comparable to CJC-1295 in the context of GH axis stimulation for body composition purposes. No dosage, frequency, or comparative efficacy data is provided.

The speaker explicitly states that DSIP and growth hormone peptides are not mutually exclusive and can be stacked together. GH peptides work the growth hormone rhythm while DSIP works sleep architecture directly, meaning they address the same problem from different angles. This stacking approach is recommended for individuals already on a GH peptide whose deep sleep remains impaired.

The speaker differentiates DSIP from growth hormone-releasing peptides such as Sermorelin, CJC-1295, Ipamorelin, and Tesamorelin. GH peptides primarily target the growth hormone axis, with improved sleep as a secondary benefit, whereas DSIP directly targets sleep architecture and the delta state. The speaker recommends DSIP when deep sleep is the primary problem, and GH peptides when growth hormone optimization is the primary goal with sleep as a bonus.

The speaker argues that adding AOD 9604 to a stack that already includes growth hormone secretagogues or exogenous growth hormone is redundant, because elevated serum growth hormone levels already confer the lipolytic benefits AOD 9604 is intended to provide. Peptides specifically named as making AOD redundant include Tesamorelin ('Tesla'), CJC-1295, Ipamorelin ('Smurlin'), and Sermorelin. No dosages are specified.

Routine IGF-1 blood testing every quarter (approximately every 3 months) is recommended for individuals using growth hormone peptides. This is presented as a harm-reduction and optimization strategy rather than a clinical requirement. No target IGF-1 ranges are specified in the transcript.

The speaker flags chronically elevated IGF-1 levels as a safety concern, specifically noting that they can worsen insulin resistance. Quarterly lab monitoring of IGF-1 levels is recommended as a safety measure. No specific IGF-1 threshold values or dosage adjustments are provided.

Growth hormone peptides are described as mobilizing fat rather than burning it, meaning a caloric deficit or fasting stimulus is still required to achieve fat loss. The speaker explicitly warns against expecting fat loss from peptides alone without dietary intervention. This is framed as a common misconception.

A cycling protocol of 5 days on and 2 days off per week is recommended, with a total run of 4 to 5 months followed by a 1-month break. Continuous use without cycling is stated to lead to receptor desensitization, reducing efficacy over time. No specific dosages are mentioned.

The speaker lists muscle preservation, better sleep, and improved recovery as the primary expected outcomes from growth hormone peptide use. No specific dosages or quantitative outcomes are provided. These benefits are presented as taking 2–3 months to manifest.

Growth hormone peptides are described as slow-acting, requiring 2 to 3 months before noticeable results emerge. Expected benefits include muscle preservation, better sleep, and improved recovery. The speaker warns against discontinuing use at week four, characterizing it as premature.

Growth hormone release is blunted by elevated insulin levels, so injections should be administered in a fasted state. Recommended timing is morning before food, at least 2 hours after eating, or at bedtime. Bedtime is cited as the optimal injection window.

Dr. Bachmeyer states sermorelin is 'crap/garbage' and while CJC-1295 is acceptable, tesamorelin is 'much more effective especially for visceral fat.' He considers tesamorelin the superior GHRH analog choice when combined with retatrutide for body composition optimization.